
PMID- 35213965
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220301
IS  - 1999-4923 (Print)
IS  - 1999-4923 (Linking)
VI  - 14
IP  - 2
DP  - 2022 Jan 19
TI  - In Silico Searching for Alternative Lead Compounds to Treat Type 2 Diabetes
      through a QSAR and Molecular Dynamics Study.
LID - 232 [pii]
LID - 10.3390/pharmaceutics14020232 [doi]
AB  - Free fatty acid receptor 1 (FFA1) stimulates insulin secretion in pancreatic
      beta-cells. An advantage of therapies that target FFA1 is their reduced risk of
      hypoglycemia relative to common type 2 diabetes treatments. In this work,
      quantitative structure-activity relationship (QSAR) approach was used to
      construct models to identify possible FFA1 agonists by applying four different
      machine-learning algorithms. The best model (M2) meets the Tropsha's test
      requirements and has the statistics parameters R(2) = 0.843, Q(2)CV = 0.785, and 
      Q(2)ext = 0.855. Also, coverage of 100% of the test set based on the
      applicability domain analysis was obtained. Furthermore, a deep analysis based on
      the ADME predictions, molecular docking, and molecular dynamics simulations was
      performed. The lipophilicity and the residue interactions were used as relevant
      criteria for selecting a candidate from the screening of the DiaNat and DrugBank 
      databases. Finally, the FDA-approved drugs bilastine, bromfenac, and fenofibric
      acid are suggested as potential and lead FFA1 agonists.
FAU - Cabrera, Nicolas
AU  - Cabrera N
AD  - Department of Biomedical Engineering, Texas A&M University, College Station, TX
      77843, USA.
FAU - Cuesta, Sebastian A
AU  - Cuesta SA
AD  - Department of Chemistry, Manchester Institute of Biotechnology, The University of
      Manchester, 131 Princess Street, Manchester M1 7DN, UK.
AD  - Grupo de Quimica Computacional y Teorica (QCT-USFQ), Departamento de Ingenieria
      Quimica, Universidad San Francisco de Quito, Diego de Robles y via Interoceanica,
      Quito 170901, Ecuador.
FAU - Mora, Jose R
AU  - Mora JR
AUID- ORCID: 0000-0001-6128-9504
AD  - Grupo de Quimica Computacional y Teorica (QCT-USFQ), Departamento de Ingenieria
      Quimica, Universidad San Francisco de Quito, Diego de Robles y via Interoceanica,
      Quito 170901, Ecuador.
FAU - Calle, Luis
AU  - Calle L
AD  - Faculty of Pharmacy, University of Granada, 18011 Granada, Spain.
AD  - Facultad de Ciencias Medicas, Instituto de Investigacion e Innovacion en Salud
      Integral, Universidad Catolica Santiago de Guayaquil, Guayaquil 09013493,
      Ecuador.
FAU - Marquez, Edgar A
AU  - Marquez EA
AUID- ORCID: 0000-0002-7503-1528
AD  - Grupo de Investigaciones en Quimica y Biologia, Departamento de Quimica y
      Biologia, Facultad de Ciencias Exactas, Universidad del Norte, Carrera 51B, Km 5,
      via Puerto Colombia, Barranquilla 081007, Colombia.
FAU - Kaunas, Roland
AU  - Kaunas R
AD  - Department of Biomedical Engineering, Texas A&M University, College Station, TX
      77843, USA.
FAU - Paz, Jose Luis
AU  - Paz JL
AUID- ORCID: 0000-0002-6177-7919
AD  - Departamento Academico de Quimica Inorganica, Facultad de Quimica e Ingenieria
      Quimica, Universidad Nacional Mayor de San Marcos, Cercado de Lima 15081, Peru.
LA  - eng
PT  - Journal Article
DEP - 20220119
PL  - Switzerland
TA  - Pharmaceutics
JT  - Pharmaceutics
JID - 101534003
PMC - PMC8879932
OTO - NOTNLM
OT  - agonits of FFA1
OT  - free fatty acid receptor 1
OT  - molecular docking
OT  - molecular dynamics
OT  - type 2 diabetes
EDAT- 2022/02/27 06:00
MHDA- 2022/02/27 06:01
CRDT- 2022/02/26 01:01
PHST- 2021/11/17 00:00 [received]
PHST- 2021/12/28 00:00 [revised]
PHST- 2022/01/07 00:00 [accepted]
PHST- 2022/02/26 01:01 [entrez]
PHST- 2022/02/27 06:00 [pubmed]
PHST- 2022/02/27 06:01 [medline]
AID - pharmaceutics14020232 [pii]
AID - 10.3390/pharmaceutics14020232 [doi]
PST - epublish
SO  - Pharmaceutics. 2022 Jan 19;14(2). pii: pharmaceutics14020232. doi:
      10.3390/pharmaceutics14020232.

PMID- 33241943
OWN - NLM
STAT- MEDLINE
DCOM- 20210208
LR  - 20210208
IS  - 1029-046X (Electronic)
IS  - 1026-776X (Linking)
VI  - 32
IP  - 1
DP  - 2021 Jan
TI  - QSAR and molecular docking modelling of anti-leishmanial activities of organic
      selenium and tellurium compounds.
PG  - 29-50
LID - 10.1080/1062936X.2020.1848914 [doi]
AB  - Leishmaniasis affects mainly rural areas and the poorest people in the world. A
      computational study of the antileishmanial activity of organic selenium and
      tellurium compounds was performed. The 3D structures of the compounds were
      optimized at the wb97xd/lanl2dz level and used in the quantitative
      structure-activity relationship (QSAR) analysis. The antileishmanial activity was
      measured by L. donovani beta carbonic anhydrase inhibition (Ki) and the
      half-maximal inhibitory concentration (IC50) against L. infantum amastigotes. The
      dataset was divided into training (75%) and test sets (25%) by using a k-means
      clustering algorithm. For pKi prediction, model M3 with seven 3D topographic
      descriptors was characterized by the following statistical parameters: r (2) =
      0.879, Q (2) LOO = 0.822, and Q (2) ext = 0.840. For pIC50 prediction, model M12 
      with six attributes was characterized by the following statistical parameters: r 
      (2) = 0.907, Q (2) LOO = 0.824, and Q (2) ext = 0.795. Both models met all the
      requirements of Tropsha s test, which implies predictions of pIC50 and pKi
      activities with high accuracy. Concomitantly, favourable interactions of the
      sulphonamide group with the Zn atom in the protein were revealed by the docking
      analysis.
FAU - Cabrera, N
AU  - Cabrera N
AUID- ORCID: https://orcid.org/0000-0002-9678-6823
AD  - Department of Biomedical Engineering, Texas A&M University , College Station, TX,
      USA.
FAU - Mora, J R
AU  - Mora JR
AUID- ORCID: https://orcid.org/0000-0001-6128-9504
AD  - Grupo de Quimica Computacional y Teorica (QCT-USFQ), Departamento de Ingenieria
      Quimica, Universidad San Francisco de Quito , Quito, Ecuador.
FAU - Marquez, E
AU  - Marquez E
AUID- ORCID: https://orcid.org/0000-0002-7503-1528
AD  - Grupo de Investigaciones en Quimica y Biologia, Departamento de Quimica y
      Biologia, Facultad de Ciencias Exactas, Universidad del Norte , Barranquilla,
      Colombia.
FAU - Flores-Morales, V
AU  - Flores-Morales V
AUID- ORCID: https://orcid.org/0000-0003-4540-1011
AD  - Laboratorio de Sintesis Asimetrica y Bioenergetica (LSAyB), Ingenieria Quimica
      (UACQ), Program of Doctorate in Sciences with Orientation in Molecular Medicine, 
      Academic Unit of Human Medicine and Health Sciences, Universidad Autonoma de
      Zacatecas , Zacatecas, Mexico.
FAU - Calle, L
AU  - Calle L
AD  - Instituto de Investigacion e Innovacion en Salud Integral (ISAIN), Facultad de
      Ciencias Medicas, Universidad Catolica Santiago de Guayaquil , Guayaquil,
      Ecuador.
FAU - Cortes, E
AU  - Cortes E
AD  - Grupo de Investigacion en Ciencias Naturales y Exactas, Departamento de Ciencias 
      Naturales y Exactas, Universidad de la Costa , Barranquilla, Colombia.
LA  - eng
PT  - Journal Article
DEP - 20201126
PL  - England
TA  - SAR QSAR Environ Res
JT  - SAR and QSAR in environmental research
JID - 9440156
RN  - 0 (Antiprotozoal Agents)
RN  - 0 (Selenium Compounds)
RN  - NQA0O090ZJ (Tellurium)
SB  - IM
MH  - Antiprotozoal Agents/*pharmacology
MH  - Leishmania donovani/*drug effects
MH  - Leishmania infantum/*drug effects
MH  - *Molecular Docking Simulation
MH  - *Quantitative Structure-Activity Relationship
MH  - Selenium Compounds/*pharmacology
MH  - Tellurium/*pharmacology
OTO - NOTNLM
OT  - Leishmaniasis
OT  - QSAR
OT  - docking analysis
OT  - organic selenium compounds
OT  - protozoan parasites
EDAT- 2020/11/27 06:00
MHDA- 2021/02/09 06:00
CRDT- 2020/11/26 12:06
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2021/02/09 06:00 [medline]
PHST- 2020/11/26 12:06 [entrez]
AID - 10.1080/1062936X.2020.1848914 [doi]
PST - ppublish
SO  - SAR QSAR Environ Res. 2021 Jan;32(1):29-50. doi: 10.1080/1062936X.2020.1848914.
      Epub 2020 Nov 26.

PMID- 33172092
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 25
IP  - 21
DP  - 2020 Nov 6
TI  - Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible
      Inhibitors of the SARS-CoV-2 M(pro) Protease.
LID - E5172 [pii]
LID - 10.3390/molecules25215172 [doi]
AB  - Wuhan, China was the epicenter of the first zoonotic transmission of the severe
      acute respiratory syndrome coronavirus clade 2 (SARS-CoV-2) in December 2019 and 
      it is the causative agent of the novel human coronavirus disease 2019 (COVID-19).
      Almost from the beginning of the COVID-19 outbreak several attempts were made to 
      predict possible drugs capable of inhibiting the virus replication. In the
      present work a drug repurposing study is performed to identify potential
      SARS-CoV-2 protease inhibitors. We created a Quantitative Structure-Activity
      Relationship (QSAR) model based on a machine learning strategy using hundreds of 
      inhibitor molecules of the main protease (M(pro)) of the SARS-CoV coronavirus.
      The QSAR model was used for virtual screening of a large list of drugs from the
      DrugBank database. The best 20 candidates were then evaluated in-silico against
      the M(pro) of SARS-CoV-2 by using docking and molecular dynamics analyses.
      Docking was done by using the Gold software, and the free energies of binding
      were predicted with the MM-PBSA method as implemented in AMBER. Our results
      indicate that levothyroxine, amobarbital and ABP-700 are the best potential
      inhibitors of the SARS-CoV-2 virus through their binding to the M(pro) enzyme.
      Five other compounds showed also a negative but small free energy of binding:
      nikethamide, nifurtimox, rebimastat, apomine and rebastinib.
FAU - Tejera, Eduardo
AU  - Tejera E
AD  - Grupo de Bio-Quimioinformatica, Universidad de Las Americas, Quito 170513,
      Ecuador.
AD  - Facultad de Ingenieria y Ciencias Aplicadas, Universidad de Las Americas, Quito
      170513, Ecuador.
FAU - Munteanu, Cristian R
AU  - Munteanu CR
AUID- ORCID: 0000-0002-5628-2268
AD  - Faculty of Computer Science, Centre for Information and Communications Technology
      Research (CITIC), University of A Coruna, 15007 A Coruna, Spain.
AD  - Biomedical Research Institute of A Coruna (INIBIC), University Hospital Complex
      of A Coruna (CHUAC), 15006 A Coruna, Spain.
FAU - Lopez-Cortes, Andres
AU  - Lopez-Cortes A
AUID- ORCID: 0000-0003-1503-1929
AD  - Centro de Investigacion Genetica y Genomica, Facultad de Ciencias de la Salud
      Eugenio Espejo, Universidad UTE, Quito 170129, Ecuador.
AD  - Latin American Network for Implementation and Validation of Clinical
      Pharmacogenomics Guidelines (RELIVAF-CYTED), 28029 Madrid, Spain.
FAU - Cabrera-Andrade, Alejandro
AU  - Cabrera-Andrade A
AUID- ORCID: 0000-0001-9702-6618
AD  - Grupo de Bio-Quimioinformatica, Universidad de Las Americas, Quito 170513,
      Ecuador.
AD  - Carrera de Enfermeria, Facultad de Ciencias de la Salud, Universidad de Las
      Americas, Quito 170513, Ecuador.
FAU - Perez-Castillo, Yunierkis
AU  - Perez-Castillo Y
AUID- ORCID: 0000-0002-3710-0035
AD  - Grupo de Bio-Quimioinformatica, Universidad de Las Americas, Quito 170513,
      Ecuador.
AD  - Escuela de Ciencias Fisicas y Matematicas, Universidad de Las Americas, Quito
      170513, Ecuador.
LA  - eng
PT  - Journal Article
DEP - 20201106
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Antiviral Agents)
RN  - 0 (Protease Inhibitors)
RN  - 0 (Small Molecule Libraries)
RN  - EC 3.4.22.- (3C-like protease, SARS coronavirus)
RN  - EC 3.4.22.28 (Coronavirus 3C Proteases)
RN  - GWH6IJ239E (Amobarbital)
RN  - Q51BO43MG4 (Thyroxine)
SB  - IM
MH  - Amobarbital/pharmacology
MH  - Antiviral Agents/chemistry/*pharmacology
MH  - Binding Sites
MH  - COVID-19/*drug therapy
MH  - Computer Simulation
MH  - Coronavirus 3C Proteases/*antagonists & inhibitors
MH  - Drug Discovery/*methods
MH  - Drug Repositioning/*methods
MH  - Humans
MH  - Machine Learning
MH  - Molecular Docking Simulation
MH  - Molecular Dynamics Simulation
MH  - Pandemics
MH  - Protease Inhibitors/chemistry/*pharmacology
MH  - Protein Binding
MH  - Quantitative Structure-Activity Relationship
MH  - SARS-CoV-2/drug effects/*enzymology
MH  - Small Molecule Libraries/chemistry
MH  - Software
MH  - Thermodynamics
MH  - Thyroxine/pharmacology
PMC - PMC7664330
OTO - NOTNLM
OT  - COVID-19
OT  - QSAR
OT  - SARS-CoV-2
OT  - drugs repurposing
OT  - molecular dynamics
EDAT- 2020/11/12 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/11 01:02
PHST- 2020/09/26 00:00 [received]
PHST- 2020/10/28 00:00 [revised]
PHST- 2020/11/04 00:00 [accepted]
PHST- 2020/11/11 01:02 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - molecules25215172 [pii]
AID - 10.3390/molecules25215172 [doi]
PST - epublish
SO  - Molecules. 2020 Nov 6;25(21). pii: molecules25215172. doi:
      10.3390/molecules25215172.

PMID- 31861689
OWN - NLM
STAT- MEDLINE
DCOM- 20200520
LR  - 20200520
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 25
IP  - 1
DP  - 2019 Dec 19
TI  - Modeling the Antileukemia Activity of Ellipticine-Related Compounds: QSAR and
      Molecular Docking Study.
LID - E24 [pii]
LID - 10.3390/molecules25010024 [doi]
AB  - The antileukemia cancer activity of organic compounds analogous to ellipticine
      representes a critical endpoint in the understanding of this dramatic disease. A 
      molecular modeling simulation on a dataset of 23 compounds, all of which comply
      with Lipinski's rules and have a structure analogous to ellipticine, was
      performed using the quantitative structure activity relationship (QSAR)
      technique, followed by a detailed docking study on three different proteins
      significantly involved in this disease (PDB IDs: SYK, PI3K and BTK). As a result,
      a model with only four descriptors (HOMO, softness, AC1RABAMBID, and TS1KFABMID) 
      was found to be robust enough for prediction of the antileukemia activity of the 
      compounds studied in this work, with an R(2) of 0.899 and Q(2) of 0.730. A
      favorable interaction between the compounds and their target proteins was found
      in all cases; in particular, compounds 9 and 22 showed high activity and binding 
      free energy values of around -10 kcal/mol. Theses compounds were evaluated in
      detail based on their molecular structure, and some modifications are suggested
      herein to enhance their biological activity. In particular, compounds 22_1, 22_2,
      9_1, and 9_2 are indicated as possible new, potent ellipticine derivatives to be 
      synthesized and biologically tested.
FAU - Marquez, Edgar
AU  - Marquez E
AD  - Grupo de Investigacion en Quimica y Biologia, Departamento de Quimica y Biologia,
      Universidad del Norte, Cra 51B, Km 5, via Puerto Colombia, Barranquilla 081007,
      Colombia.
FAU - Mora, Jose R
AU  - Mora JR
AD  - Grupo de Quimica computacional y teorica (QCT-USFQ) & instituto de Simulacion
      Computacional (ISC-USF), Departamento de Ingenieria Quimica, Colegio Politecnico 
      de Ciencias e Ingenieria, Diego de Robles, y via Interoceanica, Universidad San
      Francisco de Quito, Quito 170901, Ecuador.
FAU - Flores-Morales, Virginia
AU  - Flores-Morales V
AD  - Laboratorio de Sintesis Asimetrica y Bioenergetica (LSAyB), Ingenieria Quimica
      (UACQ), Program of Doctorate in Sciences with orientation in Molecular Medicine, 
      Academic Unit of Human Medicine and Health Sciences, Universidad Autonoma de
      Zacatecas, Campus XXI Km 6 Carr. Zac-Gdl Edificio 6, 98160 Zacatecas, Mexico.
FAU - Insuasty, Daniel
AU  - Insuasty D
AD  - Grupo de Investigacion en Quimica y Biologia, Departamento de Quimica y Biologia,
      Universidad del Norte, Cra 51B, Km 5, via Puerto Colombia, Barranquilla 081007,
      Colombia.
FAU - Calle, Luis
AU  - Calle L
AD  - Instituto de Biomedicina, Facultad de Medicina, Universidad Catolica Santiago de 
      Guayaquil, Guayaquil 09013493, Ecuador.
LA  - eng
PT  - Journal Article
DEP - 20191219
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Ellipticines)
RN  - EC 2.7.10.2 (Agammaglobulinaemia Tyrosine Kinase)
RN  - EC 2.7.10.2 (BTK protein, human)
RN  - EC 2.7.10.2 (SYK protein, human)
RN  - EC 2.7.10.2 (Syk Kinase)
SB  - IM
MH  - Agammaglobulinaemia Tyrosine Kinase/chemistry/metabolism
MH  - Antineoplastic Agents/*chemical synthesis/chemistry/pharmacology
MH  - Cell Line, Tumor
MH  - Density Functional Theory
MH  - Ellipticines/*chemical synthesis/chemistry/pharmacology
MH  - Humans
MH  - Leukemia/drug therapy/*metabolism
MH  - Models, Molecular
MH  - Molecular Docking Simulation
MH  - Molecular Dynamics Simulation
MH  - Molecular Structure
MH  - Phosphatidylinositol 3-Kinases/chemistry/metabolism
MH  - Quantitative Structure-Activity Relationship
MH  - Syk Kinase/chemistry/*metabolism
PMC - PMC6982814
OTO - NOTNLM
OT  - QSAR
OT  - cancer
OT  - leukemia
OT  - molecular descriptors
OT  - molecular modeling
COIS- The authors declare no conflict of interest.
EDAT- 2019/12/22 06:00
MHDA- 2020/05/21 06:00
CRDT- 2019/12/22 06:00
PHST- 2019/10/30 00:00 [received]
PHST- 2019/12/11 00:00 [revised]
PHST- 2019/12/16 00:00 [accepted]
PHST- 2019/12/22 06:00 [entrez]
PHST- 2019/12/22 06:00 [pubmed]
PHST- 2020/05/21 06:00 [medline]
AID - molecules25010024 [pii]
AID - 10.3390/molecules25010024 [doi]
PST - epublish
SO  - Molecules. 2019 Dec 19;25(1). pii: molecules25010024. doi:
      10.3390/molecules25010024.

PMID- 30513742
OWN - NLM
STAT- MEDLINE
DCOM- 20190211
LR  - 20200225
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 23
IP  - 12
DP  - 2018 Dec 1
TI  - Classical QSAR and Docking Simulation of 4-Pyridone Derivatives for Their
      Antimalarial Activity.
LID - E3166 [pii]
LID - 10.3390/molecules23123166 [doi]
AB  - In this work, the minimum energy structures of 22 4-pyridone derivatives have
      been optimized at Density Functional Theory level, and several quantum molecular,
      including electronic and thermodynamic descriptors, were computed for these
      substrates in order to obtain a statistical and meaningful QSAR equation. In this
      sense, by using multiple linear regressions, five mathematical models have been
      obtained. The best model with only four descriptors (r(2) = 0.86, Q(2) = 0.92,
      S.E.P = 0.38) was validated by the leave-one-out cross-validation method. The
      antimalarial activity can be explained by the combination of the four mentioned
      descriptors e.g., electronic potential, dipolar momentum, partition coefficient
      and molar refractivity. The statistical parameters of this model suggest that it 
      is robust enough to predict the antimalarial activity of new possible compounds; 
      consequently, three small chemical modifications into the structural core of
      these compounds were performed specifically on the most active compound of the
      series (compound 13). These three new suggested compounds were leveled as 13A,
      13B and 13C, and the predicted biological antimalarial activity is 0.02 microM,
      0.03 microM, and 0.07 microM, respectively. In order to complement these results 
      focused on the possible action mechanism of the substrates, a docking simulation 
      was included for these new structures as well as for the compound 13 and the
      docking scores (binding affinity) obtained for the interaction of these
      substrates with the cytochrome bc1, were -7.5, -7.2, -6.9 and -7.5 kcal/mol for
      13A, 13B, 13C and compound 13, respectively, which suggests that these compounds 
      are good candidates for its biological application in this illness.
FAU - Flores-Sumoza, Maryury
AU  - Flores-Sumoza M
AD  - Laboratorio de Fisicoquimica Organica y Quimica Computacional, Escuela de
      Ciencias, Departamento de Quimica, Universidad de Oriente, Barcelona 6001,
      Venezuela. maryuryfs@yahoo.com.
FAU - Alcazar, Jackson J
AU  - Alcazar JJ
AD  - Departamento de Quimica, Pontificia Universidad Catolica de Chile, Casilla 306,
      Santiago 6094411, Chile. jacksonalcazar@gmail.com.
FAU - Marquez, Edgar
AU  - Marquez E
AUID- ORCID: 0000-0002-7503-1528
AD  - Grupo de Investigaciones en Quimica y Biologia, Departamento de Quimica y
      Biologia, Facultad de Ciencias Exactas, Universidad del Norte, Carrera 51B, Km 5,
      via Puerto Colombia, Barranquilla 081007, Colombia. ebrazon@uninorte.edu.co.
FAU - Mora, Jose R
AU  - Mora JR
AUID- ORCID: 0000-0001-6128-9504
AD  - Grupo de Quimica computacional y teorica (QCT-USFQ) & instituto de Simulacion
      Computacional (ISC-USF) Colegio Politecnico de Ciencias e Ingenieria Diego de
      Robles, y Via Interoceanica, Universidad San Francisco de Quito, Quito 170901,
      Ecuador. jrmora@usfq.edu.ec.
FAU - Lezama, Jesus
AU  - Lezama J
AD  - Laboratorio de Fisicoquimica Organica y Quimica Computacional, Escuela de
      Ciencias, Departamento de Quimica, Universidad de Oriente, Barcelona 6001,
      Venezuela. jlezgar@gmail.com.
FAU - Puello, Esneyder
AU  - Puello E
AD  - Grupo de Investigacion en Oxi/Hidrotratamiento Catalitico y Nuevos Materiales,
      Programa de Quimica-Ciencias Basicas, Universidad del Atlantico, Barranquilla
      081001, Colombia. snypollqco@yahoo.com.
LA  - eng
PT  - Journal Article
DEP - 20181201
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Antimalarials)
RN  - 0 (Pyridones)
RN  - 3P2MV07G53 (4-pyridone)
SB  - IM
MH  - Algorithms
MH  - Antimalarials/*chemistry/*pharmacology
MH  - Inhibitory Concentration 50
MH  - *Molecular Docking Simulation
MH  - *Molecular Dynamics Simulation
MH  - Molecular Structure
MH  - Parasitic Sensitivity Tests
MH  - Pyridones/*chemistry/*pharmacology
MH  - *Quantitative Structure-Activity Relationship
PMC - PMC6321536
OTO - NOTNLM
OT  - DFT
OT  - computational study
OT  - molecular descriptors
OT  - nitrogen compounds
EDAT- 2018/12/06 06:00
MHDA- 2019/02/12 06:00
CRDT- 2018/12/06 06:00
PHST- 2018/10/13 00:00 [received]
PHST- 2018/11/21 00:00 [revised]
PHST- 2018/11/22 00:00 [accepted]
PHST- 2018/12/06 06:00 [entrez]
PHST- 2018/12/06 06:00 [pubmed]
PHST- 2019/02/12 06:00 [medline]
AID - molecules23123166 [pii]
AID - 10.3390/molecules23123166 [doi]
PST - epublish
SO  - Molecules. 2018 Dec 1;23(12). pii: molecules23123166. doi:
      10.3390/molecules23123166.

PMID- 30430931
OWN - NLM
STAT- MEDLINE
DCOM- 20190107
LR  - 20190107
IS  - 1875-5305 (Electronic)
IS  - 0929-8665 (Linking)
VI  - 25
IP  - 11
DP  - 2018
TI  - Classification-based QSAR Models for the Prediction of the Bioactivity of
      ACE-inhibitor Peptides.
PG  - 1015-1023
LID - 10.2174/0929866525666181114145658 [doi]
AB  - BACKGROUND: Local classification models were used to establish Quantitative
      Structure- Activity Relationships (QSARs) of bioactive di-, tri- and
      tetrapeptides, with their capacity to inhibit Angiotensin Converting Enzyme
      (ACE). These discrete models can thus predict this activity for other peptides
      obtained from functional foods. These types of peptides allow some foods to be
      considered nutraceuticals. METHOD: A database of 313 molecules of di-, tri- and
      tetrapeptides was investigated and antihypertensive activities of peptides,
      expressed as log (1/IC50), were separated into two qualitative classes: low
      activity (inactive) was associated with experimental values under the 66th
      percentile and active peptides with values above this threshold. Chemicals were
      divided into a training set, including 70% of the peptides, and a test set for
      external validation. Genetic algorithms-variable subset selection coupled with
      the kNN and N3 local classifiers were applied to select the best subset of
      molecular descriptors from a pool of 953 Dragon descriptors. Both models were
      validated on the test peptides. RESULTS: The N3 model turned out to be superior
      to the kNN model when the classification focused on identifying the most active
      peptides.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at
      epub@benthamscience.net.
FAU - Tripaldi, Piercosimo
AU  - Tripaldi P
AD  - Facultad de Ciencia y Tecnologia, Universidad del Azuay, Av. 24 de Mayo 7-77 y
      Hernan Malo, Cuenca, Ecuador.
FAU - Perez-Gonzalez, Andres
AU  - Perez-Gonzalez A
AD  - Facultad de Ciencia y Tecnologia, Universidad del Azuay, Av. 24 de Mayo 7-77 y
      Hernan Malo, Cuenca, Ecuador.
FAU - Rojas, Cristian
AU  - Rojas C
AD  - Facultad de Ciencia y Tecnologia, Universidad del Azuay, Av. 24 de Mayo 7-77 y
      Hernan Malo, Cuenca, Ecuador.
FAU - Radax, Johann
AU  - Radax J
AD  - Facultad de Medicina, Universidad del Azuay, Av. 24 de Mayo 7-77 y Hernan Malo,
      Cuenca, Ecuador.
FAU - Ballabio, Davide
AU  - Ballabio D
AD  - Milano Chemometrics and QSAR Research Group, Department of Earth and
      Environmental Sciences, University of Milano Bicocca, Milan, Italy.
FAU - Todeschini, Roberto
AU  - Todeschini R
AD  - Milano Chemometrics and QSAR Research Group, Department of Earth and
      Environmental Sciences, University of Milano Bicocca, Milan, Italy.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Protein Pept Lett
JT  - Protein and peptide letters
JID - 9441434
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Oligopeptides)
RN  - EC 3.4.15.1 (Peptidyl-Dipeptidase A)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/*chemistry/*pharmacology
MH  - Databases, Protein
MH  - Inhibitory Concentration 50
MH  - Models, Statistical
MH  - Oligopeptides/*chemistry/*pharmacology
MH  - Peptidyl-Dipeptidase A/*metabolism
MH  - *Quantitative Structure-Activity Relationship
OTO - NOTNLM
OT  - ACE
OT  - Bioactive peptides
OT  - Dragon descriptors
OT  - N3
OT  - QSAR
OT  - kNN.
EDAT- 2018/11/16 06:00
MHDA- 2019/01/08 06:00
CRDT- 2018/11/16 06:00
PHST- 2018/04/19 00:00 [received]
PHST- 2018/10/05 00:00 [revised]
PHST- 2018/10/30 00:00 [accepted]
PHST- 2018/11/16 06:00 [pubmed]
PHST- 2019/01/08 06:00 [medline]
PHST- 2018/11/16 06:00 [entrez]
AID - PPL-EPUB-94537 [pii]
AID - 10.2174/0929866525666181114145658 [doi]
PST - ppublish
SO  - Protein Pept Lett. 2018;25(11):1015-1023. doi: 10.2174/0929866525666181114145658.

PMID- 29231145
OWN - NLM
STAT- MEDLINE
DCOM- 20180308
LR  - 20180605
IS  - 1873-4294 (Electronic)
IS  - 1568-0266 (Linking)
VI  - 17
IP  - 30
DP  - 2018 Feb 9
TI  - Learning from Multiple Classifier Systems: Perspectives for Improving Decision
      Making of QSAR Models in Medicinal Chemistry.
PG  - 3269-3288
LID - 10.2174/1568026618666171212111018 [doi]
AB  - Quantitative Structure - Activity Relationship (QSAR) modeling has been widely
      used in medicinal chemistry and computational toxicology for many years. Today,
      as the amount of chemicals is increasing dramatically, QSAR methods have become
      pivotal for the purpose of handling the data, identifying a decision, and
      gathering useful information from data processing. The advances in this field
      have paved a way for numerous alternative approaches that require deep
      mathematics in order to enhance the learning capability of QSAR models. One of
      these directions is the use of Multiple Classifier Systems (MCSs) that
      potentially provide a means to exploit the advantages of manifold learning
      through decomposition frameworks, while improving generalization and predictive
      performance. In this paper, we presented MCS as a next generation of QSAR
      modeling techniques and discuss the chance to mining the vast number of models
      already published in the literature. We systematically revisited the theoretical 
      frameworks of MCS as well as current advances in MCS application for QSAR
      practice. Furthermore, we illustrated our idea by describing ensemble approaches 
      on modeling histone deacetylase (HDACs) inhibitors. We expect that our analysis
      would contribute to a better understanding about MCS application and its future
      perspectives for improving the decision making of QSAR models.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at
      epub@benthamscience.org.
FAU - Pham-The, Hai
AU  - Pham-The H
AD  - Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Hanoi, Vietnam.
FAU - Nam, Nguyen-Hai
AU  - Nam NH
AD  - Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Hanoi, Vietnam.
FAU - Nga, Doan-Viet
AU  - Nga DV
AD  - School of Medicine and Pharmacy, Vietnam National University (VNU), 144 Xuan
      Thuy, Hanoi, Vietnam.
FAU - Hai, Dang Thanh
AU  - Hai DT
AD  - University of Engineering and Technology, Vietnam National University, 144 Xuan
      Thuy, Hanoi, Vietnam.
FAU - Dieguez-Santana, Karel
AU  - Dieguez-Santana K
AD  - Faculty of Life Sciences, Amazonian State University, Puyo, Pastaza, Ecuador.
FAU - Marrero-Poncee, Yovani
AU  - Marrero-Poncee Y
AD  - Universidad San Francisco de Quito (USFQ), Grupo de Medicina Molecular y
      Traslacional (MeM&T), Colegio de Ciencias de la Salud (COCSA),Escuela de
      Medicina, Edificio de Especialidades Medicas, Quito, Ecuador.
FAU - Castillo-Garit, Juan A
AU  - Castillo-Garit JA
AD  - Unidad de Toxicologia Experimental, Universidad de Ciencias Medicas "Dr. Serafin 
      Ruiz de Zarate Ruiz" de Villa Clara, Cuba.
FAU - Casanola-Martin, Gerardo M
AU  - Casanola-Martin GM
AD  - Department of Systems and Computer Engineering, Carleton University, Ottawa, ON, 
      Canada.
FAU - Le-Thi-Thu, Huong
AU  - Le-Thi-Thu H
AD  - School of Medicine and Pharmacy, Vietnam National University (VNU), 144 Xuan
      Thuy, Hanoi, Vietnam.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Top Med Chem
JT  - Current topics in medicinal chemistry
JID - 101119673
RN  - 0 (Histone Deacetylase Inhibitors)
SB  - IM
MH  - Animals
MH  - Chemistry, Pharmaceutical/*methods
MH  - Decision Making
MH  - Histone Deacetylase Inhibitors/*chemistry/*pharmacology
MH  - Humans
MH  - Learning
MH  - Models, Molecular
MH  - *Quantitative Structure-Activity Relationship
OTO - NOTNLM
OT  - Artificial neural network
OT  - Ensemble design
OT  - Histone Deacetylase (HDAC) inhibitors
OT  - Histone deacetylase
OT  - Multiple classifier system
OT  - Quantitative Structure -Activity Relationships (QSAR)
EDAT- 2017/12/13 06:00
MHDA- 2018/03/09 06:00
CRDT- 2017/12/13 06:00
PHST- 2017/11/02 00:00 [received]
PHST- 2017/11/14 00:00 [revised]
PHST- 2017/11/22 00:00 [accepted]
PHST- 2017/12/13 06:00 [pubmed]
PHST- 2018/03/09 06:00 [medline]
PHST- 2017/12/13 06:00 [entrez]
AID - CTMC-EPUB-87353 [pii]
AID - 10.2174/1568026618666171212111018 [doi]
PST - ppublish
SO  - Curr Top Med Chem. 2018 Feb 9;17(30):3269-3288. doi:
      10.2174/1568026618666171212111018.

PMID- 28274840
OWN - NLM
STAT- MEDLINE
DCOM- 20180404
LR  - 20181113
IS  - 1878-5832 (Electronic)
IS  - 1359-6446 (Linking)
VI  - 22
IP  - 7
DP  - 2017 Jul
TI  - Systemic QSAR and phenotypic virtual screening: chasing butterflies in drug
      discovery.
PG  - 994-1007
LID - S1359-6446(17)30107-1 [pii]
LID - 10.1016/j.drudis.2017.02.004 [doi]
AB  - Current advances in systems biology suggest a new change of paradigm reinforcing 
      the holistic nature of the drug discovery process. According to the principles of
      systems biology, a simple drug perturbing a network of targets can trigger
      complex reactions. Therefore, it is possible to connect initial events with final
      outcomes and consequently prioritize those events, leading to a desired effect.
      Here, we introduce a new concept, 'Systemic Chemogenomics/Quantitative
      Structure-Activity Relationship (QSAR)'. To elaborate on the concept, relevant
      information surrounding it is addressed. The concept is challenged by
      implementing a systemic QSAR approach for phenotypic virtual screening (VS) of
      candidate ligands acting as neuroprotective agents in Parkinson's disease (PD).
      The results support the suitability of the approach for the phenotypic
      prioritization of drug candidates.
CI  - Copyright (c) 2017 Elsevier Ltd. All rights reserved.
FAU - Cruz-Monteagudo, Maykel
AU  - Cruz-Monteagudo M
AD  - CIQUP/Departamento de Quimica e Bioquimica, Faculdade de Ciencias, Universidade
      do Porto, Porto 4169-007, Portugal. Electronic address: gmailkelcm@yahoo.es.
FAU - Schurer, Stephan
AU  - Schurer S
AD  - Department of Pharmacology, Miller School of Medicine and Center for
      Computational Science, University of Miami, Miami, FL 33136, USA.
FAU - Tejera, Eduardo
AU  - Tejera E
AD  - Instituto de Investigaciones Biomedicas (IIB), Universidad de Las Americas,
      170513 Quito, Ecuador.
FAU - Perez-Castillo, Yunierkis
AU  - Perez-Castillo Y
AD  - Seccion Fisico Quimica y Matematicas, Departamento de Quimica, Universidad
      Tecnica Particular de Loja, San Cayetano Alto S/N, EC1101608 Loja, Ecuador.
FAU - Medina-Franco, Jose L
AU  - Medina-Franco JL
AD  - Universidad Nacional Autonoma de Mexico, Departamento de Farmacia, Facultad de
      Quimica, Avenida Universidad 3000, Mexico City, 04510, Mexico.
FAU - Sanchez-Rodriguez, Aminael
AU  - Sanchez-Rodriguez A
AD  - Departamento de Ciencias Naturales, Universidad Tecnica Particular de Loja, Calle
      Paris S/N, EC1101608 Loja, Ecuador.
FAU - Borges, Fernanda
AU  - Borges F
AD  - CIQUP/Departamento de Quimica e Bioquimica, Faculdade de Ciencias, Universidade
      do Porto, Porto 4169-007, Portugal. Electronic address: fborges@fc.up.pt.
LA  - eng
GR  - U54 CA189205/CA/NCI NIH HHS/United States
GR  - U54 HL127624/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Review
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20170306
PL  - England
TA  - Drug Discov Today
JT  - Drug discovery today
JID - 9604391
SB  - IM
MH  - *Drug Discovery
MH  - Genomics
MH  - Humans
MH  - Phenotype
MH  - *Quantitative Structure-Activity Relationship
PMC - PMC5487293
MID - NIHMS857937
EDAT- 2017/03/10 06:00
MHDA- 2018/04/05 06:00
CRDT- 2017/03/10 06:00
PHST- 2016/11/16 00:00 [received]
PHST- 2017/02/02 00:00 [revised]
PHST- 2017/02/27 00:00 [accepted]
PHST- 2017/03/10 06:00 [pubmed]
PHST- 2018/04/05 06:00 [medline]
PHST- 2017/03/10 06:00 [entrez]
AID - S1359-6446(17)30107-1 [pii]
AID - 10.1016/j.drudis.2017.02.004 [doi]
PST - ppublish
SO  - Drug Discov Today. 2017 Jul;22(7):994-1007. doi: 10.1016/j.drudis.2017.02.004.
      Epub 2017 Mar 6.

PMID- 28161994
OWN - NLM
STAT- MEDLINE
DCOM- 20170306
LR  - 20211204
IS  - 1029-046X (Electronic)
IS  - 1026-776X (Linking)
VI  - 28
IP  - 1
DP  - 2017 Jan
TI  - Conformation-dependent QSAR approach for the prediction of inhibitory activity of
      bromodomain modulators.
PG  - 41-58
LID - 10.1080/1062936X.2017.1278616 [doi]
AB  - Epigenetic drug discovery is a promising research field with growing interest in 
      the scientific community, as evidenced by the number of publications and the
      large amount of structure-epigenetic activity information currently available in 
      the public domain. Computational methods are valuable tools to analyse and
      understand the activity of large compound collections from their structural
      information. In this manuscript, QSAR models to predict the inhibitory activity
      of a diverse and heterogeneous set of 88 organic molecules against the
      bromodomains BRD2, BRD3 and BRD4 are presented. A conformation-dependent
      representation of the chemical structures was established using the RDKit
      software and a training and test set division was performed. Several two-linear
      and three-linear QuBiLS-MIDAS molecular descriptors ( www.tomocomd.com ) were
      computed to extract the geometric structural features of the compounds studied.
      QuBiLS-MIDAS-based features sets, to be used in the modelling, were selected
      using dimensionality reduction strategies. The multiple linear regression
      procedure coupled with a genetic algorithm were employed to build the predictive 
      models. Regression models containing between 6 to 9 variables were developed and 
      assessed according to several internal and external validation methods. Analyses 
      of outlier compounds and the applicability domain for each model were performed. 
      As a result, the models against BRD2 and BRD3 with 8 variables and the model with
      9 variables against BRD4 were those with the best overall performance according
      to the criteria accounted for. The results obtained suggest that the models
      proposed will be a good tool for studying the inhibitory activities of drug
      candidates against the bromodomains considered during epigenetic drug discovery.
FAU - Garcia-Jacas, C R
AU  - Garcia-Jacas CR
AD  - a Instituto de Quimica, Universidad Nacional Autonoma de Mexico (UNAM) , Ciudad
      de Mexico , Mexico.
AD  - b Escuela de Sistemas y Computacion , Pontificia Universidad Catolica del Ecuador
      Sede Esmeraldas (PUCESE) , Esmeraldas , Ecuador.
AD  - c Grupo de Investigacion de Bioinformatica , Universidad de las Ciencias
      Informaticas (UCI) , La Habana , Cuba.
FAU - Martinez-Mayorga, K
AU  - Martinez-Mayorga K
AD  - a Instituto de Quimica, Universidad Nacional Autonoma de Mexico (UNAM) , Ciudad
      de Mexico , Mexico.
FAU - Marrero-Ponce, Y
AU  - Marrero-Ponce Y
AD  - d Grupo de Medicina Molecular y Traslacional (MeM&T) , Universidad San Francisco 
      de Quito (USFQ) , Quito , Ecuador.
AD  - e Grupo de Investigacion Ambiental (GIA) , Fundacion Universitaria Tecnologica de
      Comfenalco , Bolivar , Colombia.
FAU - Medina-Franco, J L
AU  - Medina-Franco JL
AD  - f Departamento de Farmacia , Universidad Nacional Autonoma de Mexico (UNAM) ,
      Ciudad de Mexico , Mexico.
LA  - eng
PT  - Journal Article
DEP - 20170206
PL  - England
TA  - SAR QSAR Environ Res
JT  - SAR and QSAR in environmental research
JID - 9440156
RN  - 0 (BRD2 protein, human)
RN  - 0 (BRD3 protein, human)
RN  - 0 (BRD4 protein, human)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Nuclear Proteins)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Transcription Factors)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Cell Cycle Proteins
MH  - Computer Simulation
MH  - Enzyme Inhibitors/*chemistry/*pharmacology
MH  - Epigenesis, Genetic/drug effects
MH  - Models, Statistical
MH  - Molecular Conformation
MH  - Nuclear Proteins/*antagonists & inhibitors/chemistry
MH  - Protein Serine-Threonine Kinases/*antagonists & inhibitors/chemistry
MH  - *Quantitative Structure-Activity Relationship
MH  - RNA-Binding Proteins/*antagonists & inhibitors/chemistry
MH  - Transcription Factors/*antagonists & inhibitors/chemistry
OTO - NOTNLM
OT  - 3D molecular descriptors
OT  - Applicability domain
OT  - QSAR
OT  - QuBiLS-MIDAS
OT  - TOMOCOMD-CARDD
OT  - bromodomains
OT  - epigenetic drug discovery
EDAT- 2017/02/07 06:00
MHDA- 2017/03/07 06:00
CRDT- 2017/02/07 06:00
PHST- 2017/02/07 06:00 [pubmed]
PHST- 2017/03/07 06:00 [medline]
PHST- 2017/02/07 06:00 [entrez]
AID - 10.1080/1062936X.2017.1278616 [doi]
PST - ppublish
SO  - SAR QSAR Environ Res. 2017 Jan;28(1):41-58. doi: 10.1080/1062936X.2017.1278616.
      Epub 2017 Feb 6.

PMID- 27707004
OWN - NLM
STAT- MEDLINE
DCOM- 20170316
LR  - 20170316
IS  - 1029-046X (Electronic)
IS  - 1026-776X (Linking)
VI  - 27
IP  - 12
DP  - 2016 Dec
TI  - N-tuple topological/geometric cutoffs for 3D N-linear algebraic molecular
      codifications: variability, linear independence and QSAR analysis.
PG  - 949-975
AB  - Novel N-tuple topological/geometric cutoffs to consider specific inter-atomic
      relations in the QuBiLS-MIDAS framework are introduced in this manuscript. These 
      molecular cutoffs permit the taking into account of relations between more than
      two atoms by using (dis-)similarity multi-metrics and the concepts related with
      topological and Euclidean-geometric distances. To this end, the kth two-, three- 
      and four-tuple topological and geometric neighbourhood quotient (NQ) total (or
      local-fragment) spatial-(dis)similarity matrices are defined, to represent 3D
      information corresponding to the relations between two, three and four atoms of
      the molecular structures that satisfy certain cutoff criteria. First, an analysis
      of a diverse chemical space for the most common values of
      topological/Euclidean-geometric distances, bond/dihedral angles,
      triangle/quadrilateral perimeters, triangle area and volume was performed in
      order to determine the intervals to take into account in the cutoff procedures. A
      variability analysis based on Shannon's entropy reveals that better distribution 
      patterns are attained with the descriptors based on the cutoffs proposed
      (QuBiLS-MIDAS NQ-MDs) with regard to the results obtained when all inter-atomic
      relations are considered (QuBiLS-MIDAS KA-MDs - 'Keep All'). A principal
      component analysis shows that the novel molecular cutoffs codify chemical
      information captured by the respective QuBiLS-MIDAS KA-MDs, as well as
      information not captured by the latter. Lastly, a QSAR study to obtain deeper
      knowledge of the contribution of the proposed methods was carried out, using four
      molecular datasets (steroids (STER), angiotensin converting enzyme (ACE),
      thermolysin inhibitors (THER) and thrombin inhibitors (THR)) widely used as
      benchmarks in the evaluation of several methodologies. One to four variable QSAR 
      models based on multiple linear regression were developed for each compound
      dataset following the original division into training and test sets. The results 
      obtained reveal that the novel cutoff procedures yield superior performances
      relative to those of the QuBiLS-MIDAS KA-MDs in the prediction of the biological 
      activities considered. From the results achieved, it can be suggested that the
      proposed N-tuple topological/geometric cutoffs constitute a relevant criteria for
      generating MDs codifying particular atomic relations, ultimately useful in
      enhancing the modelling capacity of the QuBiLS-MIDAS 3D-MDs.
FAU - Garcia-Jacas, C R
AU  - Garcia-Jacas CR
AD  - a Escuela de Sistemas y Computacion , Pontificia Universidad Catolica del Ecuador
      Sede Esmeraldas (PUCESE) , Esmeraldas , Ecuador.
AD  - b Grupo de Investigacion de Bioinformatica , Instituto de Quimica, Universidad
      Nacional Autonoma de Mexico (UNAM) , Ciudad de Mexico , D.F, Mexico.
AD  - c Grupo de Investigacion de Bioinformatica , Universidad de las Ciencias
      Informaticas (UCI) , La Habana , Cuba.
FAU - Marrero-Ponce, Y
AU  - Marrero-Ponce Y
AD  - d Grupo de Medicina Molecular y Traslacional (MeM&T) , Universidad San Francisco 
      de Quito (USFQ) , Quito , Ecuador.
AD  - e Instituto de Simulacion Computacional (ISC-USFQ), Universidad San Francisco de 
      Quito (USFQ) , Quito , Ecuador.
FAU - Barigye, S J
AU  - Barigye SJ
AD  - g Department of Chemistry , McGill University , Montreal , Quebec , Canada.
FAU - Hernandez-Ortega, T
AU  - Hernandez-Ortega T
AD  - c Grupo de Investigacion de Bioinformatica , Universidad de las Ciencias
      Informaticas (UCI) , La Habana , Cuba.
FAU - Cabrera-Leyva, L
AU  - Cabrera-Leyva L
AD  - f Grupo de Investigacion de Inteligencia Artificial (AIRES) , Universidad de
      Camaguey , Camaguey , Cuba.
FAU - Fernandez-Castillo, A
AU  - Fernandez-Castillo A
AD  - c Grupo de Investigacion de Bioinformatica , Universidad de las Ciencias
      Informaticas (UCI) , La Habana , Cuba.
LA  - eng
PT  - Journal Article
DEP - 20161006
PL  - England
TA  - SAR QSAR Environ Res
JT  - SAR and QSAR in environmental research
JID - 9440156
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Antithrombins)
RN  - 0 (Steroids)
RN  - EC 3.4.24.27 (Thermolysin)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/chemistry
MH  - Antithrombins/chemistry
MH  - Linear Models
MH  - *Models, Chemical
MH  - Molecular Structure
MH  - Principal Component Analysis
MH  - *Quantitative Structure-Activity Relationship
MH  - Steroids/chemistry
MH  - Thermolysin/antagonists & inhibitors
OTO - NOTNLM
OT  - *3D molecular descriptors
OT  - *N-tuple molecular cutoffs
OT  - *QSAR
OT  - *QuBiLS-MIDAS
OT  - *TOMOCOMD-CARDD
EDAT- 2016/10/07 06:00
MHDA- 2017/03/17 06:00
CRDT- 2016/10/07 06:00
PHST- 2016/10/07 06:00 [pubmed]
PHST- 2017/03/17 06:00 [medline]
PHST- 2016/10/07 06:00 [entrez]
AID - 10.1080/1062936X.2016.1231714 [doi]
PST - ppublish
SO  - SAR QSAR Environ Res. 2016 Dec;27(12):949-975. doi:
      10.1080/1062936X.2016.1231714. Epub 2016 Oct 6.

PMID- 26355653
OWN - NLM
STAT- MEDLINE
DCOM- 20160823
LR  - 20171116
IS  - 1549-960X (Electronic)
IS  - 1549-9596 (Linking)
VI  - 55
IP  - 10
DP  - 2015 Oct 26
TI  - Harmonization of QSAR Best Practices and Molecular Docking Provides an Efficient 
      Virtual Screening Tool for Discovering New G-Quadruplex Ligands.
PG  - 2094-110
LID - 10.1021/acs.jcim.5b00415 [doi]
AB  - Telomeres and telomerase are key players in tumorogenesis. Among the various
      strategies proposed for telomerase inhibition or telomere uncapping, the
      stabilization of telomeric G-quadruplex (G4) structures is a very promising one. 
      Additionally, G4 stabilizing ligands also act over tumors mediated by the
      alternative elongation of telomeres. Accordingly, the discovery of novel
      compounds able to act on telomeres and/or inhibit the telomerase enzyme by
      stabilizing DNA telomeric G4 structures as well as the development of approaches 
      efficiently prioritizing such compounds constitute active areas of research in
      computational medicinal chemistry and anticancer drug discovery. In this
      direction, we applied a virtual screening strategy based on the rigorous
      application of QSAR best practices and its harmonized integration with
      structure-based methods. More than 600,000 compounds from commercial databases
      were screened, the first 99 compounds were prioritized, and 21 commercially
      available and structurally diverse candidates were purchased and submitted to
      experimental assays. Such strategy proved to be highly efficient in the
      prioritization of G4 stabilizer hits, with a hit rate of 23.5%. The best G4
      stabilizer hit found exhibited a shift in melting temperature from FRET assay of 
      +7.3 degrees C at 5 muM, while three other candidates also exhibited a promising 
      stabilizing profile. The two most promising candidates also exhibited a good
      telomerase inhibitory ability and a mild inhibition of HeLa cells growth. None of
      these candidates showed antiproliferative effects in normal fibroblasts. Finally,
      the proposed virtual screening strategy proved to be a practical and reliable
      tool for the discovery of novel G4 ligands which can be used as starting points
      of further optimization campaigns.
FAU - Castillo-Gonzalez, Daimel
AU  - Castillo-Gonzalez D
AD  - ARNA Laboratory, IECB, University of Bordeaux , F-33600 Pessac, France.
AD  - ARNA Laboratory, INSERM, U869, F-33000 Bordeaux, France.
FAU - Mergny, Jean-Louis
AU  - Mergny JL
AD  - ARNA Laboratory, IECB, University of Bordeaux , F-33600 Pessac, France.
AD  - ARNA Laboratory, INSERM, U869, F-33000 Bordeaux, France.
FAU - De Rache, Aurore
AU  - De Rache A
AD  - ARNA Laboratory, IECB, University of Bordeaux , F-33600 Pessac, France.
AD  - ARNA Laboratory, INSERM, U869, F-33000 Bordeaux, France.
FAU - Perez-Machado, Gisselle
AU  - Perez-Machado G
AD  - Molecular Simulation and Drug Design Group, Centro de Bioactivos Quimicos (CBQ), 
      Central University of Las Villas , Santa Clara, Villa Clara 54830, Cuba.
AD  - Department of Physiology, Faculty of Medicine, University of Valencia , Valencia 
      46010, Valencia, Spain.
AD  - Department of Pharmacy and Pharmaceutical Technology, University of Valencia ,
      Burjassot 46100, Valencia, Spain.
FAU - Cabrera-Perez, Miguel Angel
AU  - Cabrera-Perez MA
AD  - Molecular Simulation and Drug Design Group, Centro de Bioactivos Quimicos (CBQ), 
      Central University of Las Villas , Santa Clara, Villa Clara 54830, Cuba.
AD  - Department of Pharmacy and Pharmaceutical Technology, University of Valencia ,
      Burjassot 46100, Valencia, Spain.
AD  - Department of Engineering, Area of Pharmacy and Pharmaceutical Technology, Miguel
      Hernandez University , 03550 Sant Joan d'Alacant, Alicante, Alicante, Spain.
FAU - Nicolotti, Orazio
AU  - Nicolotti O
AD  - Dipartimento di Farmacia-Scienze, Universita degli Studi di Bari "Aldo Moro'' ,
      Via Orabona 4, 70125 Bari, Bari, Italy.
FAU - Introcaso, Antonellina
AU  - Introcaso A
AD  - Dipartimento di Farmacia-Scienze, Universita degli Studi di Bari "Aldo Moro'' ,
      Via Orabona 4, 70125 Bari, Bari, Italy.
FAU - Mangiatordi, Giuseppe Felice
AU  - Mangiatordi GF
AD  - Dipartimento di Farmacia-Scienze, Universita degli Studi di Bari "Aldo Moro'' ,
      Via Orabona 4, 70125 Bari, Bari, Italy.
FAU - Guedin, Aurore
AU  - Guedin A
AD  - ARNA Laboratory, IECB, University of Bordeaux , F-33600 Pessac, France.
AD  - ARNA Laboratory, INSERM, U869, F-33000 Bordeaux, France.
FAU - Bourdoncle, Anne
AU  - Bourdoncle A
AD  - ARNA Laboratory, IECB, University of Bordeaux , F-33600 Pessac, France.
AD  - ARNA Laboratory, INSERM, U869, F-33000 Bordeaux, France.
FAU - Garrigues, Teresa
AU  - Garrigues T
AD  - Department of Pharmacy and Pharmaceutical Technology, University of Valencia ,
      Burjassot 46100, Valencia, Spain.
FAU - Pallardo, Federico
AU  - Pallardo F
AD  - Department of Physiology, Faculty of Medicine, University of Valencia , Valencia 
      46010, Valencia, Spain.
FAU - Cordeiro, M Natalia D S
AU  - Cordeiro MN
FAU - Paz-Y-Mino, Cesar
AU  - Paz-Y-Mino C
AD  - Instituto de Investigaciones Biomedicas (IIB), Universidad de Las Americas ,
      170513 Quito, Pichincha, Ecuador.
FAU - Tejera, Eduardo
AU  - Tejera E
AD  - Instituto de Investigaciones Biomedicas (IIB), Universidad de Las Americas ,
      170513 Quito, Pichincha, Ecuador.
FAU - Borges, Fernanda
AU  - Borges F
FAU - Cruz-Monteagudo, Maykel
AU  - Cruz-Monteagudo M
AD  - Instituto de Investigaciones Biomedicas (IIB), Universidad de Las Americas ,
      170513 Quito, Pichincha, Ecuador.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150918
PL  - United States
TA  - J Chem Inf Model
JT  - Journal of chemical information and modeling
JID - 101230060
RN  - 0 (Acridines)
RN  - 0 (Ligands)
RN  - Z7C5CD91WI (BRACO-19)
SB  - IM
MH  - Acridines/*chemistry
MH  - Cell Proliferation
MH  - Crystallography, X-Ray
MH  - Drug Discovery
MH  - *Drug Evaluation, Preclinical
MH  - Fibroblasts/chemistry
MH  - *G-Quadruplexes
MH  - HeLa Cells
MH  - Humans
MH  - Ligands
MH  - *Molecular Docking Simulation
MH  - Molecular Structure
MH  - Quantitative Structure-Activity Relationship
MH  - Telomere/chemistry
EDAT- 2015/09/12 06:00
MHDA- 2016/08/24 06:00
CRDT- 2015/09/11 06:00
PHST- 2015/09/11 06:00 [entrez]
PHST- 2015/09/12 06:00 [pubmed]
PHST- 2016/08/24 06:00 [medline]
AID - 10.1021/acs.jcim.5b00415 [doi]
PST - ppublish
SO  - J Chem Inf Model. 2015 Oct 26;55(10):2094-110. doi: 10.1021/acs.jcim.5b00415.
      Epub 2015 Sep 18.
